Checkpoint inhibitors are a groundbreaking class of cancer treatment, but they come with two frustrating challenges. In some cases, tumors show no initial response, rendering the therapy ineffective ...

Immune checkpoint inhibitors have revolutionised cancer treatment by unleashing cytotoxic T-cell responses against tumours, yet a significant subset of patients who initially benefit will ultimately ...

A major pillar of cancer immunotherapy involves stimulating T cells, the specialized killers of the immune system, to attack ...

Researchers have uncovered a clue to why immune checkpoint inhibitors—cancer therapies that release the immune "brakes" ...

Combination immune checkpoint inhibitor therapy (ICI) with ipilimumab (anti–cytotoxic T-lymphocyte–associated protein 4) + nivolumab (anti–PD-1) in untreated, metastatic melanoma has achieved a ...

Immune checkpoint inhibitors have transformed the management of advanced malignancies by releasing the brakes on antitumour T-cell responses. Agents targeting programmed cell death protein 1 (PD-1), ...

A multinational collaboration co-led by the Garvan Institute of Medical Research has uncovered a potential explanation for why some cancer patients receiving a type of immunotherapy called checkpoint ...

Please provide your email address to receive an email when new articles are posted on . DESTIN, Fla. — Inflammatory arthritis as a result of immune checkpoint cancer therapy remains a pressing ...

This work addresses an important evidence gap in the use of immune checkpoint inhibitors among patients with pre-existing ...

General practitioner examining a patient's hand for signs of rheumatoid arthritis. A breakthrough in cancer and autoimmune disease therapy could unlock a whole new frontier in medicine. Scientists are ...

Immune checkpoint inhibitors are well known as a form of cancer treatment. Researchers at UZH have now identified a new, important function of these inhibitors: promotion of tissue healing. This ...

A recent study found that monthly prices of checkpoint inhibitors decreased only slightly from 2015 to 2024, with declines in annual average sales prices ranging from 0.21% to 4.85%. "Prices of ...